Artiva Biotherapeutics, Inc.
Business
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell-based therapies for autoimmune diseases and cancers. It offers AlloNK, a cryopreserved NK cell therapy evaluated in combination with B-cell targeted monoclonal antibodies, as well as CAR-NK product candidates (e.g., AB-201, AB-205) and collaborator-funded programs. The company’s business segments include AlloNK clinical development in autoimmunity and oncology, CAR‑NK pipeline programs, partnered trials and manufacturing operations. It supplies therapies to U.S. clinical sites, supports investigator-initiated trials, and holds ex-APAC commercialization rights with global collaboration channels.
Summary from filing dated 2025-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| License and development support revenue (including related party amounts of $0 and $251, respectively) | 0 | 251,000 | 569,000 | |
| Research and development (including related party amounts of $76 and $3,168, respectively) | 70 | 50 | 50 | |
| General and administrative | 20 | 17 | 14 | |
| Total operating expenses | 90 | 68 | 64 | |
| Loss from operations | −90 | −67 | −31 | |
| Interest income | 6 | 5 | 3 | |
| Change in fair value of SAFEs (including related party amounts of $0 and $2,911, respectively) | 0 | −4 | −707,000 | |
| Other (expense) income, net | −14,000 | 157,000 | 195,000 | |
| Total other income, net | 6 | 2 | 2 | |
| Net loss | −84 | −65 | −29 | |
| Net loss per share - basic | −3.43 | −5.81 | −35.78 | |
| Net loss per share - diluted | −3.43 | −5.81 | −35.78 | |
| Weighted average common shares outstanding - basic | 24 | 11 | 802,747 | |
| Weighted average common shares outstanding - diluted | 24 | 11 | 802,747 | |
| Unrealized gain (loss) on investments, net | 232,000 | −437,000 | — | |
| Comprehensive loss | −84 | −66 | −28 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 27 | 40 | 54 | — | |
| Short-term investments | 81 | 145 | 23 | — | |
| Other receivables (including related party amounts of $61 and $0, respectively) | 67,000 | 146,000 | 724,000 | — | |
| Prepaid expenses and other current assets | 5 | 3 | 1 | — | |
| Total current assets | 113 | 189 | 80 | — | |
| Restricted cash | 461,000 | 258,000 | 258,000 | — | |
| Property and equipment, net | 7 | 6 | 8 | — | |
| Operating lease right-of-use assets | 11 | 14 | 17 | — | |
| Financing lease right-of-use asset | 212,000 | 261,000 | — | — | |
| Other long-term assets | 458,000 | 267,000 | 392,000 | — | |
| Total assets | 131 | 210 | 105 | — | |
| Accounts payable (including related party amounts of $0 and $276, respectively) | 355,000 | 1 | 614,000 | — | |
| Accrued expenses (including related party amounts of $0 and $713, respectively) | 10 | 7 | 8 | — | |
| Current portion of operating lease liabilities | 3 | 4 | 4 | — | |
| Current portion of financing lease liability | 44,000 | 122,000 | — | — | |
| Other current liabilities | 73,000 | — | — | — | |
| Total current liabilities | 13 | 12 | 12 | — | |
| Operating lease liabilities, net of current portion | 8 | 11 | 13 | — | |
| Financing lease liability, net of current portion | — | 44,000 | — | — | |
| Other non-current liabilities | — | 73,000 | 73,000 | — | |
| Total liabilities | 21 | 23 | 51 | — | |
| Commitments and contingencies (Note 10) | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; zero shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — | — | — | |
| Common stock, $0.0001 par value; 700,000,000 shares authorized at December 31, 2025 and December 31, 2024; 24,595,550 and 24,291,607 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,000 | 3,000 | — | — | |
| Additional paid-in capital | 440 | 433 | 19 | — | |
| Accumulated other comprehensive income (loss) | 103,000 | −129,000 | 308,000 | — | |
| Accumulated deficit | −331 | −247 | −181 | — | |
| Total stockholders' equity | 110 | 187 | −162 | −141 | |
| Total liabilities and stockholders' equity | 131 | 210 | 105 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 3 | 2 | 2 | |
| Stock-based compensation | 7 | 7 | 7 | |
| Accretion of discounts and amortization of premiums on investments, net | −2 | −2 | −456,000 | |
| Accounts receivable (including related party amounts of $0 and $569, respectively) | 0 | 1 | −510,000 | |
| Other receivables (including related party amounts of $(61) and $607, respectively) | 79,000 | 578,000 | −724,000 | |
| Prepaid expenses and other current assets | −2 | −2 | 516,000 | |
| Other long-term assets | −191,000 | 125,000 | 139,000 | |
| Accounts payable (including related party amounts of $ (276) and $76, respectively) | −760,000 | 519,000 | −408,000 | |
| Accrued expenses (including related party amounts of $(735) and $(1,447), respectively) | 2 | −659,000 | −912,000 | |
| Operating lease right-of-use asset and lease liabilities, net | −21,000 | 43,000 | 145,000 | |
| Net cash used in operating activities | −77 | −55 | −47 | |
| Purchases of property and equipment | −3 | −642,000 | −3 | |
| Purchases of investments | −45 | −176 | — | |
| Maturities of investments | 111 | 56 | — | |
| Net cash provided by (used in) investing activities | 63 | −120 | −26 | |
| Proceeds from issuance of common stock, net of commissions | 0 | 167 | — | |
| Proceeds from exercise of stock options | 138,000 | 51,000 | 10,000 | |
| Proceeds from purchase of ESPP shares | 233,000 | 0 | — | |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | −230,000 | 0 | — | |
| Payments on finance leases | −132,000 | −149,000 | — | |
| Cash paid in connection with IPO offering costs | 0 | −4 | — | |
| Net cash provided by financing activities | 9,000 | 162 | 24 | |
| Net decrease in cash, cash equivalents and restricted cash | −13 | −13 | −49 | |
| Right-of-use asset obtained in exchange for new operating lease liability | 442,000 | 0 | — | |
| Reduction in operating lease liabilities and right-of-use-assets from remeasurement | 546,000 | 0 | — | |
| Property and equipment purchases in accounts payable and accrued liabilities | 292,000 | 57,000 | 18,000 | |
| Conversion of SAFE notes to common stock | 0 | 29 | — | |
| Conversion of preferred stock to common stock | 0 | 216 | — | |
| Non-cash additions to financing leases | 0 | 241,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Artiva Biotherapeutics, Inc.'s CIK number?
Artiva Biotherapeutics, Inc.'s SEC CIK number is 0001817241 (1817241). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Artiva Biotherapeutics, Inc.'s SEC filings?
All of Artiva Biotherapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Artiva Biotherapeutics, Inc. last report earnings?
Artiva Biotherapeutics, Inc. (ARTV) most recently filed an earnings 8-K with the SEC on May 8, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-213239). This is Artiva Biotherapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Artiva Biotherapeutics, Inc.'s most recent earnings 8-K?
Artiva Biotherapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 8, 2026 under accession 0001193125-26-213239. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Artiva Biotherapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →